|
gptkbp:instanceOf
|
gptkb:chemical_compound
|
|
gptkbp:alsoKnownAs
|
gptkb:Rivaroxaban
|
|
gptkbp:approvedBy
|
2008
prevention of stroke in atrial fibrillation
treatment of deep vein thrombosis
treatment of pulmonary embolism
|
|
gptkbp:ATCCode
|
gptkb:B01AF01
|
|
gptkbp:bioavailability
|
80-100% (10 mg dose)
|
|
gptkbp:CASNumber
|
366789-02-8
|
|
gptkbp:contraindication
|
active pathological bleeding
severe hypersensitivity to rivaroxaban
|
|
gptkbp:developedBy
|
gptkb:Bayer
|
|
gptkbp:discoveredIn
|
2000s
|
|
gptkbp:eliminationHalfLife
|
5-9 hours
|
|
gptkbp:excretion
|
urine
feces
|
|
gptkbp:hasMolecularFormula
|
gptkb:C19H18ClN3O5S
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
BAY 59-7939
|
|
gptkbp:IUPACName
|
gptkb:5-chloro-N-({(5S)-2-oxo-3-[4-(3-oxomorpholin-4-yl)phenyl]-1,3-oxazolidin-5-yl}methyl)thiophene-2-carboxamide
|
|
gptkbp:KEGGID
|
D08917
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:marketedAs
|
gptkb:Xarelto
|
|
gptkbp:mechanismOfAction
|
direct factor Xa inhibitor
|
|
gptkbp:metabolism
|
liver (CYP3A4, CYP2J2)
|
|
gptkbp:pregnancyCategory
|
C (US)
|
|
gptkbp:proteinBinding
|
92-95%
|
|
gptkbp:PubChem_CID
|
gptkb:CHEMBL112911
gptkb:DB06228
9875401
8051413
|
|
gptkbp:routeOfAdministration
|
oral
|
|
gptkbp:sideEffect
|
gptkb:anemia
nausea
bleeding
dizziness
|
|
gptkbp:UNII
|
Y191O07L5X
|
|
gptkbp:usedAs
|
gptkb:anticoagulant
|
|
gptkbp:bfsParent
|
gptkb:Xarelto
|
|
gptkbp:bfsLayer
|
6
|